Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Novo Nordisk moves further into CV diseases with Corvidia acquisition

Cardio-renal specialist Corvidia Therapeutics has been acquired for $725m by diabetes giant Novo Nordisk. This deal builds on Novo Nordisk’s recent move into the CV space through outcomes trials of its diabetes drugs – semaglutide and liraglutide – and is closely linked to the promise of Corvidia’s first-in-class lead compound, ziltivekimab.

Close
Close
Close

Go Top